Inventor · disambiguated record
Yanke Liang
Also filed as: LIANG YANKE
40 granted patents·21 pending applications·257 citations·filing 2015–2025
97Inventor score
Files withC4 THERAPEUTICS INC29DANA FARBER CANCER INST INC16HOFFMANN LA ROCHE7MASSACHUSETTS GEN HOSPITAL5BROAD INST INC3
Top patents by PatentIndex Score
61 records- 0197US11185592B2Spirocyclic degronimers for target protein degradationC4 THERAPEUTICS INC·Filed 2020·Granted Nov 30, 2021·20 cites·26 claims
- 0297US10660968B2Spirocyclic degronimers for target protein degradationC4 THERAPEUTICS INC·Filed 2018·Granted May 26, 2020·32 cites·35 claims
- 0396US12209091B2Isoindolinone derivatives as selective allosteric inhibitors of Egfr mutant cancersHOFFMANN LA ROCHE·Filed 2020·Granted Jan 28, 2025·7 cites·30 claims
- 0496US10905768B1Heterocyclic degronimers for target protein degradationC4 THERAPEUTICS INC·Filed 2020·Granted Feb 2, 2021·31 cites·20 claims
- 0596US10849982B2C3-carbon linked glutarimide degronimers for target protein degradationC4 THERAPEUTICS INC·Filed 2018·Granted Dec 1, 2020·43 cites·17 claims
- 0696US10646575B2Heterocyclic degronimers for target protein degradationC4 THERAPEUTICS INC·Filed 2018·Granted May 12, 2020·32 cites·28 claims
- 0795US12048747B2Substituted piperidine Degronimers for Target Protein degradationC4 THERAPEUTICS INC·Filed 2020·Granted Jul 30, 2024·4 cites·22 claims
- 0895US11725011B2Bicyclic urea kinase inhibitors and uses thereofBROAD INST INC·Filed 2020·Granted Aug 15, 2023·4 cites·9 claims
- 0995US11673902B2Isoindolinone and indazole compounds for the degradation of EGFRC4 THERAPEUTICS INC·Filed 2022·Granted Jun 13, 2023·3 cites·29 claims
- 1095US10287268B2Imidazolyl kinase inhibitors and uses thereofDANA FARBER CANCER INST INC·Filed 2015·Granted May 14, 2019·11 cites·23 claims
- 1194US11708354B22-benzopyrazinyl-n-heteroaryl-2-phenyl-acetamide compoundsHOFFMANN LA ROCHE·Filed 2020·Granted Jul 25, 2023·3 cites·16 claims
- 1294US11459335B2N/O-linked Degrons and Degronimers for protein degradationC4 THERAPEUTICS INC·Filed 2019·Granted Oct 4, 2022·8 cites·23 claims
- 1394US10870651B2Inhibitors of cyclin-dependent kinase 7 (CDK7)DANA FARBER CANCER INST INC·Filed 2015·Granted Dec 22, 2020·9 cites·36 claims
- 1493US12371442B2Isoindolinone and indazole compounds for the degradation of EGFRC4 THERAPEUTICS INC·Filed 2023·Granted Jul 29, 2025·1 cites·28 claims
- 1593US11992531B2C3-carbon linked glutarimide degronimers for target protein degradationC4 THERAPEUTICS INC·Filed 2020·Granted May 28, 2024·3 cites·31 claims
- 1693US10975058B2Imidazolyl kinase inhibitors and uses thereofDANA FARBER CANCER INST INC·Filed 2019·Granted Apr 13, 2021·6 cites·32 claims
- 1791US10265321B2Uses of salt-inducible kinase (SIK) inhibitorsDANA FARBER CANCER INST INC·Filed 2017·Granted Apr 23, 2019·10 cites·38 claims
- 1890US12048748B2Spirocyclic degronimers for target protein degradationC4 THERAPEUTICS INC·Filed 2021·Granted Jul 30, 2024·1 cites·21 claims
- 1990US10954242B2Bicyclic urea kinase inhibitors and uses thereofBROAD INST INC·Filed 2017·Granted Mar 23, 2021·9 cites·33 claims
- 2088US10457691B2Macrocyclic kinase inhibitors and uses thereofDANA FARBER CANCER INST INC·Filed 2015·Granted Oct 29, 2019·9 cites·38 claims
- 2187US12180225B2N/O-linked degrons and degronimers for protein degradationC4 THERAPEUTICS INC·Filed 2022·Granted Dec 31, 2024·1 cites·19 claims
- 2287US10882848B22-benzopyrazinyl-n-heteroaryl-2-phenyl-acetamide compoundsHOFFMANN LA ROCHE·Filed 2019·Granted Jan 5, 2021·3 cites·15 claims
- 2385US12168663B2Inhibitors of cyclin-dependent kinase 7 (CDK7)DANA FARBER CANCER INST INC·Filed 2020·Granted Dec 17, 2024·1 cites·17 claims
- 2485US12076405B2Heterocyclic degronimers for target protein degradationC4 THERAPEUTICS INC·Filed 2021·Granted Sep 3, 2024·1 cites·20 claims
- 2583US2025057957A1Spirocyclic degronimers for target protein degradationC4 THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 2683US2025121069A1Heterocyclic degronimers for target protein degradationC4 THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 2781US12486253B2Therapeutics for the degradation of mutant BRAFC4 THERAPEUTICS INC·Filed 2024·Granted Dec 2, 2025·0 cites·4 claims
- 2881US11285158B2Uses of pyrimidopyrimidinones as SIK inhibitorsMASSACHUSETTS GEN HOSPITAL·Filed 2018·Granted Mar 29, 2022·1 cites·47 claims
- 2980US12486290B2Isoindolinone and indazole compounds for the degradation of EGFRC4 THERAPEUTICS INC·Filed 2025·Granted Dec 2, 2025·0 cites·30 claims
- 3080US2025127903A1Substituted piperidine degronimers for target protein degradationC4 THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 3179US12421220B2Bicyclic-substituted glutarimide cereblon bindersC4 THERAPEUTICS INC·Filed 2024·Granted Sep 23, 2025·0 cites·26 claims
- 3279US12398145B2Bicyclic urea kinase inhibitors and uses thereofBROAD INST INC·Filed 2023·Granted Aug 26, 2025·0 cites·47 claims
- 3379US11241435B2Uses of salt-inducible kinase (SIK) inhibitors for treating osteoporosisMASSACHUSETTS GEN HOSPITAL·Filed 2017·Granted Feb 8, 2022·1 cites·27 claims
- 3479US2025382285A1Bicyclic-substituted glutarimide cereblon bindersC4 THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 3579US2025368631A1Bicyclic-substituted glutarimide cereblon bindersC4 THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 3678US10865204B2Degradation of cyclin-dependent kinase 4/6 (CDK4/6) by conjugation of CDK4/6 inhibitors with E3 ligase ligand and methods of useDANA FARBER CANCER INST INC·Filed 2017·Granted Dec 15, 2020·3 cites·30 claims
- 3778US2024245695A1Uses of pyrimidopyrimidinones as sik inhibitorsMASSACHUSETTS GEN HOSPITAL·Filed 2023·Application pending·0 cites
- 3876US12441740B2N/O-linked degrons and degronimers for protein degradationC4 THERAPEUTICS INC·Filed 2024·Granted Oct 14, 2025·0 cites·19 claims
- 3972US11827636B2Degradation of cyclin-dependent kinase 8 (CDK8) by conjugation of CDK8 inhibitors with E3 ligase ligand and methods of useDANA FARBER CANCER INST INC·Filed 2021·Granted Nov 28, 2023·0 cites·16 claims
- 4070US11878019B2Uses of pyrimidopyrimidinones as SIK inhibitorsMASSACHUSETTS GEN HOSPITAL·Filed 2021·Granted Jan 23, 2024·0 cites·25 claims
- 4170US2024199581A1Therapeutics for the degradation of mutant brafC4 THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 4269US12209076B2Imidazolyl kinase inhibitors and uses thereofDANA FARBER CANCER INST INC·Filed 2021·Granted Jan 28, 2025·0 cites·19 claims
- 4367US2020338087A9Uses of salt-inducible kinase (sik) inhibitorsDANA FARBER CANCER INST INC·Filed 2019·Application pending·0 cites
- 4465US12121521B2Uses of salt-inducible kinase (SIK) inhibitors for treating osteoporosisMASSACHUSETTS GEN HOSPITAL·Filed 2022·Granted Oct 22, 2024·0 cites·46 claims
- 4565US11247991B2Degradation of cyclin-dependent kinase 8 (CDK8) by conjugation of CDK8 inhibitors with E3 ligase ligand and methods of useDANA FARBER CANCER INST INC·Filed 2020·Granted Feb 15, 2022·0 cites·23 claims
- 4664US2025340556A1Pyrimidopyrimidone compounds and methods of use thereofSOLTEGO INC·Filed 2023·Application pending·0 cites
- 4763US2024158418A1EGFR Degraders to Treat Cancer Metastasis to the Brain or CNSC4 THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 4863US2025121070A1Compounds for the targeted degradation of smarca2C4 THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 4962US2019076539A1Amine-linked c3-glutarimide degronimers for target protein degradationC4 THERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 5061US12454521B2Targeted protein degradationC4 THERAPEUTICS INC·Filed 2021·Granted Oct 28, 2025·0 cites·25 claims
Showing the top 50 of 61 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Yanke Liang files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →